A nascent biotech field dedicated to life extension has emerged in recent years, with a variety of promising startups wanting to reverse the consequences of aging. These companies are developing medicines and therapies that fight senescence, reduce irritation, and stimulate cellular regeneration.
AgeX Therapeutics
Shown in the NYSE, AgeX Therapeutics evolves drugs and therapies that target the underlying causes of getting older and degenerative illnesses by restoring youthful regenerative capability. Brought by pioneer in tissue regeneration analysis Michael D West, the business is targeted on a number of innovative cellular immortality solutions including cloning, telomerase therapy, splice-based treatments, and more.
Calico / Alphabet / Calico Labs
As the health study and longevity technology subsidiary of Google's mother or father Alphabet, Calico is really a leading programmer of regenerative medications that fight aging. Its prospect drug applicant is really a recombinant type of GDF11 produced by researchers at Harvard University. Currently in preclinical trials, the compound has shown promise in regenerating muscle, heart, and brain tissues broken by age-related situations such as stroke and diabetes.
Longevity InTime & LessDeath
The Longevity InTime Local community is a global local community of health insurance and life fans, focused on providing information, services and products which are helping individuals extend their existence and enhance their health. The city aims to greatly help individuals live life much longer, healthier, and happier lifestyles by giving real-time information on disease danger, early analysis of serious ailments, and personalized tips for prevention.
Altos Labs / Amazon / Jeff Bezos & Yuri Milner
A team of researchers who have established eye-popping credentials in longevity study. Several domain specialists are working with Altos Labs, including Juan Carlos Izpisua Belmonte (a top practitioner and authority in regenerative medicine), Steve Horvath (a geneticist and biostatistician who developed a highly accurate molecular biomarker for aging), and Shinya Yamanaka (a Nobel Prize winner and a pioneer in cellular reprogramming).
Gero / Pfizer / Pfizer Pharmaceuticals
A preclinical-stage physics-enabled biotech firm that generates therapeutics against chronic diseases by slowing down the deterioration of individual cellular material themselves, Gero provides forged a partnership with pharma huge Pfizer. Both companies use Gero's device learning technology platform to identify potential targets for fibrotic diseases and collaborate on preclinical development and clinical trials.
Juvenescence / IPO of 2022 / Juvenescence LLC
The longevity-focused startup Juvenescence offers been able to improve over US$219.2 M in 5 rounds, which includes a Series A funding round led by Longevity Vision Fund, Grok Ventures, and IPGL. The company is based in SAN FRANCISCO BAY AREA, California, and is targeted on regenerative medication, age administration, and enhancing metabolic efficiency by utilizing artificial intelligence along with other technologies.
Elevian / IPO of 2022 / Elevian Inc
Elevian is rolling out a number of drug candidates that are capable of restoring a younger regenerative capacity in human beings and pets. The business's lead item is a recombinant version of GDF11 that has demonstrated the capability to regenerate heart, human brain, and muscle groups broken by age-related problems.